The HIP1R Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This product provides a heterogeneous pool of cells harboring targeted disruptions in the HIP1R gene, generated via CRISPR/Cas9-mediated gene disruption. The polyclonal format preserves genetic diversity and avoids clonal selection artifacts, making it suitable for bulk functional assays where population-level loss-of-function effects are studied. These cells serve as a versatile tool for investigating the role of HIP1R in endocytic trafficking and receptor signaling in a cancer-relevant context.
The host A-549 cell line was originally isolated from a 58-year-old male with lung adenocarcinoma and is a widely used model for respiratory epithelial biology and disease. A-549 cells carry an oncogenic KRAS mutation, a common driver mutation in lung adenocarcinoma, which activates MAPK and AKT signaling pathways and influences endocytic processes. As adherent lung carcinoma epithelial cells, they express epidermal growth factor receptor (EGFR) and other cell surface receptors whose internalization and signaling are tightly regulated by clathrin-mediated endocytosis. This genetic and phenotypic background makes A-549 an appropriate host for dissecting the contribution of endocytic adaptors to cancer cell behavior.
HIP1R is an endocytic adaptor that couples clathrin-mediated endocytosis to the actin cytoskeleton. It binds clathrin, actin, cortactin, HIP1, huntingtin, and the AP-2 complex, and is regulated by upstream factors such as EGF, TGF-??, and SRC kinases. HIP1R acts downstream of EGFR to facilitate clathrin-coated pit formation and receptor internalization, while also controlling actin remodeling through Arp2/3, Rac1, and Rho GTPases. Disruption of HIP1R impairs endocytosis, resulting in sustained EGFR surface presence, persistent AKT and ERK/MAPK signaling, and altered actin dynamics, ultimately affecting proliferation, migration, and receptor degradation.
In the A-549 lung adenocarcinoma model, HIP1R loss-of-function is particularly relevant because aberrant EGFR trafficking and signaling are hallmarks of lung cancer progression and drug resistance. By eliminating HIP1R, these polyclonal knockout cells exhibit altered kinetics of EGFR internalization and recycling, providing a platform to examine how endocytic defects impact oncogenic signaling networks. The interplay between KRAS-driven mitogenic signals and HIP1R-dependent endocytosis can be systematically interrogated, revealing vulnerabilities that may be exploited for therapeutic intervention. This model thus links molecular endocytic adaptor function to clinically significant phenotypes in lung cancer.
Researchers can employ these cells for western blotting of EGFR and downstream targets (p-EGFR, p-AKT, p-ERK), immunofluorescence visualization of clathrin and actin, flow cytometry of surface receptors, and EGF uptake assays to quantify endocytosis. Co-immunoprecipitation can identify HIP1R interactors such as clathrin and cortactin, while proliferation, migration, and invasion assays reveal functional consequences. RNA-seq may uncover transcriptomic changes. For further information, please contact Ascent Research.
